EHMT2 and familial pancreatic carcinoma: Pharmacologic inhibition of G9a using UNC0638 as well as genetic knock-out of G9a in pancreatic cancer models has been shown to increase sensitivity to gemcitabine as well as decrease cancer stemness [52].